Activists seek to block a Gilead patent extension on a lucrative HIV drug

In an unusual move, an advocacy group asked federal authorities to reject a request by Gilead Sciences (GILD) for a three-year patent extension on an HIV drug because the company allegedly lied about important information in its application.